Limits...
Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors.

Toyozawa S, Yamamoto Y, Ishida Y, Kondo T, Nakamura Y, Furukawa F - Acta Histochem Cytochem (2010)

Bottom Line: These receptors promote tumor growth and metastasis in response to endogenous chemokines.Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7.These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Wakayama Medical University, Wakayama, Japan. seikotoy@wakayama-med.ac.jp

ABSTRACT
Functional chemokine receptors are expressed in many malignant tumors. These receptors promote tumor growth and metastasis in response to endogenous chemokines. We analyzed the expression of CXCR4, CCR6 and CCR7 in fibrohistiocytic tumors, including dermatofibrosarcoma protuberance (DFSP), malignant fibrous histiocytoma (MFH), dermatofibroma (DF) using immunohistochemistry. We also investigated the relationship between CXCR4 and CD34, the latter of which is an immunohistochemical marker for DFSP. We observed a higher expression of CXCR4 in DFSP and MFH as compared with DF. Interestingly, a significantly higher expression of CXCR4 was detected in relapsed DFSP than in non-relapsed DFSP, but no significant differences were detected between non-relapsed DFSP and DFSP with CD34 immunostaining. Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7. These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

No MeSH data available.


Related in: MedlinePlus

CD34 immunoexpression in relapsed DFSP (×200). A. CD34 positive case of relapsed DFSP. B. CD34 negative case of relapsed DFSP.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2875858&req=5

Figure 7: CD34 immunoexpression in relapsed DFSP (×200). A. CD34 positive case of relapsed DFSP. B. CD34 negative case of relapsed DFSP.

Mentions: In the 3 relapsed DFSP cases, anti-CD34 immunoreactivity was detected in 2 cases (Fig. 7A), but not in 1 case (Fig. 7B).


Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors.

Toyozawa S, Yamamoto Y, Ishida Y, Kondo T, Nakamura Y, Furukawa F - Acta Histochem Cytochem (2010)

CD34 immunoexpression in relapsed DFSP (×200). A. CD34 positive case of relapsed DFSP. B. CD34 negative case of relapsed DFSP.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2875858&req=5

Figure 7: CD34 immunoexpression in relapsed DFSP (×200). A. CD34 positive case of relapsed DFSP. B. CD34 negative case of relapsed DFSP.
Mentions: In the 3 relapsed DFSP cases, anti-CD34 immunoreactivity was detected in 2 cases (Fig. 7A), but not in 1 case (Fig. 7B).

Bottom Line: These receptors promote tumor growth and metastasis in response to endogenous chemokines.Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7.These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Wakayama Medical University, Wakayama, Japan. seikotoy@wakayama-med.ac.jp

ABSTRACT
Functional chemokine receptors are expressed in many malignant tumors. These receptors promote tumor growth and metastasis in response to endogenous chemokines. We analyzed the expression of CXCR4, CCR6 and CCR7 in fibrohistiocytic tumors, including dermatofibrosarcoma protuberance (DFSP), malignant fibrous histiocytoma (MFH), dermatofibroma (DF) using immunohistochemistry. We also investigated the relationship between CXCR4 and CD34, the latter of which is an immunohistochemical marker for DFSP. We observed a higher expression of CXCR4 in DFSP and MFH as compared with DF. Interestingly, a significantly higher expression of CXCR4 was detected in relapsed DFSP than in non-relapsed DFSP, but no significant differences were detected between non-relapsed DFSP and DFSP with CD34 immunostaining. Moreover, MFH had strong immunoreactivity for CXCR4, CCR6 and CCR7. These findings suggest that the assessment of CXCR4 immunoreactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.

No MeSH data available.


Related in: MedlinePlus